Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer

2001/03/01 by Ernest L. Mazzaferri, Richard T. Kloos · 29 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Thyroid Cancer Diagnosis and Treatment #BRCA gene mutations in cancer #Thyroid and Parathyroid Surgery

paper · pdf · doi:10.1210/jcem.86.4.7407

Abstract

Patient variables Age 15 yr or 45 yr Age 15-45 yr Male sex Female sex Family history of thyroid cancer No family history of thyroid cancer Tumor variables Tumor 4 cm in diameter Tumor 4 cm in diameter Bilateral disease Unilateral disease Extrathyroidal extension No extrathyroidal extension Vascular Invasion (both papillary and follicular thyroid cancer) Absence of vascular invasion Cervical, or mediastinal lymph node metastases No lymph node metastases Certain tumor subtypes: Hu rthle cell, tall cell, columnar cell, diffuse sclerosis, insular variants Encapsulated papillary thyroid carcinoma, papillary microcarcinoma, cystic papillary thyroid carcinoma Marked nuclear atypia, tumor necrosis, and vascular invasion (i.e. histologic grade) Absence of nuclear atypia, tumor necrosis, and vascular invasion Tumors or metastases that concentrate radioiodine poorly or not at all Tumors or metastases that concentrate radioiodine well Distant metastases No distant metastases Modified from the NCCN guidelines for the diagnosis and treatment of thyroid cancer (3, 6).

Cited by

• Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
• Controversies, Consensus, and Collaboration in the Use of 131 I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association
• 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
• Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. [europepmc]
• Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. [europepmc]
• Measles virus for cancer therapy. [europepmc]
• The biology of the sodium iodide symporter and its potential for targeted gene delivery. [europepmc]
• Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. [europepmc]
• Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. [europepmc]
• Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. [europepmc]
• Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. [europepmc]
• The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. [europepmc]
• Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. [europepmc]
• American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. [europepmc]
• Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. [europepmc]
• Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. [europepmc]
• Cost-effectiveness analysis of papillary thyroid cancer surveillance. [europepmc]
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. [europepmc]
• TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. [europepmc]
• Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid. [europepmc]
• NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. [europepmc]
• Differentiated thyroid cancer theranostics: radioiodine and beyond. [europepmc]
• Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up. [europepmc]
• LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer. [europepmc]
• Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. [europepmc]
• Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy. [europepmc]
• Machine learning for the prediction of bone metastasis in patients with newly diagnosed thyroid cancer. [europepmc]
• Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. [europepmc]

Related

• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
• Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
• 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
• Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
• Clinical Characteristics of Subtypes of Follicular Variant Papillary Thyroid Carcinoma